Abstract
In vitro treatment of Echinococcus multilocularis and Echinococcus granulosus larval stages with the antimalarials dihydroartemisinin and artesunate (10 to 40 microM) exhibited promising results, while 6 weeks of in vivo treatment of mice infected with E. multilocularis metacestodes (200 mg/kg of body weight/day) had no effect. However, combination treatments of both drugs with albendazole led to a substantial but statistically not significant reduction in parasite weight compared to results with albendazole alone.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Albendazole / pharmacology
-
Albendazole / therapeutic use
-
Animals
-
Anti-Infective Agents* / pharmacology
-
Anti-Infective Agents* / therapeutic use
-
Antiparasitic Agents / pharmacology
-
Antiparasitic Agents / therapeutic use
-
Artemisinins* / pharmacology
-
Artemisinins* / therapeutic use
-
Drug Therapy, Combination
-
Echinococcosis / drug therapy*
-
Echinococcosis / parasitology
-
Echinococcus granulosus / drug effects
-
Echinococcus granulosus / growth & development
-
Echinococcus multilocularis* / drug effects
-
Echinococcus multilocularis* / growth & development
-
Humans
-
Larva / drug effects
-
Mice
-
Mice, Inbred BALB C
-
Nitro Compounds
-
Parasitic Sensitivity Tests
-
Thiazoles / therapeutic use
-
Treatment Outcome
Substances
-
Anti-Infective Agents
-
Antiparasitic Agents
-
Artemisinins
-
Nitro Compounds
-
Thiazoles
-
artenimol
-
artemisinin
-
Albendazole
-
nitazoxanide